Trial Profile
A Phase II, Single Arm, Multicenter, Proof-of-Mechanism Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Βeta-Thalassemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2019
Price :
$35
*
At a glance
- Drugs Bitopertin (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 16 May 2019 This trial has been discontinued in Italy, according to European Clinical Trials Database.
- 04 Dec 2018 Results assessing efficacy and safety of Bitopertin in patients with beta-thalassemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.